Abstract:Alzheimer's disease (AD) is the most common neurodegenerative disease and is characterized by progressive memory loss and cognitive dysfunction. Long non-coding RNAs (lncRNAs) have been shown to be among the most promising biomarkers and therapeutic targets of AD. Here, we aimed to investigate whether lncRNA BACE1-AS plays a role in the potential mechanisms of AD. The expression of BACE1-AS, miR-214-3p and ATG5 mRNA was detected using qRT-PCR. The expression of the LC3, P62, ATG5, Bcl-2, p-Tau and cleaved-caspase 3 proteins was examined using western blot analysis. Cell apoptosis, cytotoxicity and ROS levels were estimated using flow cytometry, an LDH kit and a DCFH-DA assay, respectively. The interaction between BACE1-AS or ATG5 and miR-214-3p was validated using a dual-luciferase reporter assay. HE staining and a TUNEL assay were employed to evaluate hippocampal neuronal injury. The BACE1-AS level was found to be upregulated in serum samples of AD patients, brain tissues of AD transgenic (Tg) mice and Aβ1-42-treated SH-SY5Y cells. Autophagy activity was increased in both Tg mice and Aβ1-42-treated cells. BACE1-AS knockdown alleviated Aβ1-42-induced cell injury. Rapamycin abolished the protective effects of sh BACE1-AS against Aβ1-42 induced cell injury. BACE1-AS indirectly regulated ATG5 expression by binding miR-214-3p. The miR-214-3p inhibitor reversed the protective effects of sh BACE1-AS and sh ATG5 against Aβ1-42-induced cell injury. Knockdown of BACE1-AS alleviated neuronal injury by repressing autophagy in vivo. Our findings demonstrate that silencing of BACE1-AS alleviated neuronal injury by regulating autophagy through the miR-214-3p/ATG5 signalling axis in AD.

Enhancing autophagy maturation with CCZ1-MON1A complex alleviates neuropathology and memory defects in Alzheimer disease models

Impairment of the autophagy–lysosomal pathway in Alzheimer's diseases: Pathogenic mechanisms and therapeutic potential

Stimulation of autophagy prevents amyloid-β peptide-induced neuritic degeneration in PC12 cells.

Autophagy Modulation for Alzheimer's Disease Therapy.

Dynamic changes of autophagic flux induced by Abeta in the brain of postmortem Alzheimer’s disease patients, animal models and cell models

Enhancing Rab7 Activity by Inhibiting TBC1D5 Expression Improves Mitophagy in Alzheimer’s Disease Models

Enhancing Rab7 Activity by Inhibiting TBC1D5 Expression Improves Mitophagy in Alzheimer's Disease Models

Connexin43 Contributes to Alzheimer’s Disease by Promoting the Mitochondria-Associated Membrane-Related Autophagy Inhibition

Corynoxine promotes TFEB/TFE3-mediated autophagy and alleviates Aő≤ pathology in Alzheimer's disease models

LncRNA BACE1-AS Promotes Autophagy-Mediated Neuronal Damage Through The miR-214-3p/ATG5 Signalling Axis In Alzheimer's Disease

Molecular Mechanism of Autophagy: Its Role in the Therapy of Alzheimer’s Disease

Connexin43 Contributes to Alzheimer's Disease by Promoting the Mitochondria-Associated Membrane-Related Autophagy Inhibition

Multidimensional autophagy nano-regulator boosts Alzheimer's disease treatment by improving both extra/intraneuronal homeostasis

HLH-30/TFEB modulates autophagy to improve proteostasis in Aβ transgenic Caenorhabditis elegans

Autophagy in Alzheimer’s disease pathogenesis: Therapeutic potential and future perspectives

Enhancing the retrograde axonal transport by curcumin promotes autophagic flux in N2a/APP695swe cells

Clemastine attenuates AD-like pathology in an AD model mouse via enhancing mTOR-mediated autophagy

Defective Autophagy and Mitophagy in Alzheimer's Disease: Mechanisms and Translational Implications

Nitazoxanide, an anti-parasitic drug, efficiently ameliorates learning and memory impairments in AD model mice

Corynoxine Promotes TFEB/TFE3-mediated Autophagy and Alleviates Aβ Pathology in Alzheimer’s Disease Models

Yizhiqingxin Formula Alleviates Cognitive Deficits and Enhances Autophagy Via Mtor Signaling Pathway Modulation in Early Onset Alzheimer's Disease Mice.